<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01592032</url>
  </required_header>
  <id_info>
    <org_study_id>CAS110775</org_study_id>
    <secondary_id>2010-023814-29</secondary_id>
    <nct_id>NCT01592032</nct_id>
  </id_info>
  <brief_title>Concentration of Antimicrobials in Catheter-lock Solutions</brief_title>
  <acronym>CONAN</acronym>
  <official_title>Concentration and Antibiotic Activity in Antibiotic Lock Solutions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinica Universidad de Navarra, Universidad de Navarra</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Navarrra Hospital (Clinica Universitaria)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Clinica Universidad de Navarra, Universidad de Navarra</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The antibiotic lock technique (ALT) is used as local treatment for Catheter-Related
      Bacteremia (CRB). It consists in the administration of a concentrated antimicrobial solution
      with a calculated volume to fill the lumen of the catheter. The lock solution is indwelled
      within the catheter for a defined period of hours or days before been removed.

      Currently, the Infectious Diseases Society of America (IDSA) Guidelines for treatment and
      management of CRB, recommends to change the antibiotic solution every 24 hours.

      The investigators expect to determine the stability of the concentration of vancomycin,
      teicoplanin, linezolid, daptomycin and tigecycline used in lock solutions, and thus to assay
      the optimal timeframe that the concentration of antibiotic used in lock solution keeps its in
      vivo antimicrobial activity.

      Study Hypothesis: An antibiotic lock solution maintains in vivo concentration and
      antimicrobial activity for at least 10 days after its infusion inside a subcutaneous port
      catheter.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective: Assess the antimicrobial concentration of catheter-lock solutions at the
      end of port indwelling time. Secondary Objectives: 1) Assess bioactivity of antimicrobials in
      lock solutions at the end of port indwelling time. 2) Assess anticoagulant activity of
      antimicrobial-lock solutions at the end of port indwelling time.

      Methods: Randomized, open, block allocation according to time of indwelling of the
      antimicrobial-lock within the ports, unicentric, clinical trial in patients older than 18
      years old with a venous port implanted at Clínica Universidad de Navarra. Intevention:
      Randomization of 5 patients into one of five antimicrobial-lock solution arms for 1, 3, 5, 7
      and 10 days according to HPLC corrected by urea gradient. Any study arm can be stopped at any
      time from day 1 to day 10, in case of antimicrobial concentration would be less than 1 mg/mL.

      At the end of each antimicrobial lock time frame of ports (1, 3, 5, 7 and 10 days), the
      antimicrobial concentration will be determined by high performance liquid chromatography
      (HPLC) and corrected by urea gradient. The cut-off for the median antimicrobial concentration
      is 1 mg/mL.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antimicrobial concentration of catheter-lock solutions at the end of port indwelling time.</measure>
    <time_frame>1 to 10 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bioactivity of antimicrobials in lock solutions at the end of port indwelling time.</measure>
    <time_frame>1 to 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anticoagulant activity of antimicrobial-lock solutions at the end of port indwelling time.</measure>
    <time_frame>1 to 10 days</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Catheter-Related Infections</condition>
  <condition>Bacteremia.</condition>
  <arm_group>
    <arm_group_label>Vancomycin antimicrobial-lock</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vancomycin antimicrobial-lock solution. Dosage: 2 mg/mL. Dosage form: liquid in syringe. Frequency: 1. Duration: from 1 to 10 days according to HPLC corrected by urea gradient.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Teicoplanin antimicrobial-lock</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Teicoplanin antimicrobial-lock solution. Dosage: 10 mg/mL. Dosage form: liquid in syringe. Frequency: 1. Duration: from 1 to 10 days according to HPLC corrected by urea gradient.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Linezolid antimicrobial-lock</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Linezolid antimicrobial-lock solution. Dosage: 1.8 mg/mL. Dosage form: liquid in syringe. Frequency: 1. Duration: from 1 to 10 days according to HPLC corrected by urea gradient.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daptomycin antimicrobial-lock</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daptomycin antimicrobial-lock solution. Dosage: 5 mg/mL. Dosage form: liquid in syringe. Frequency: 1. Duration: from 1 to 10 days according to HPLC corrected by urea gradient.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tigecycline antimicrobial-lock</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tigecycline antimicrobial-lock solution. Dosage: 4.5 mg/mL. Dosage form: liquid in syringe. Frequency: 1. Duration: from 1 to 10 days according to HPLC corrected by urea gradient.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin antimicrobial-lock solution</intervention_name>
    <description>Randomization of 5 patients into vancomycin antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.</description>
    <arm_group_label>Vancomycin antimicrobial-lock</arm_group_label>
    <other_name>vancomycin: vancomicina sala 500 mg vial.</other_name>
    <other_name>sodium heparin 1%, 5000 IU/5ml.</other_name>
    <other_name>sodium chloride 0,9% 10 ml vial.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teicoplanin antimicrobial-lock solution</intervention_name>
    <description>Randomization of 5 patients into teicoplanin antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.</description>
    <arm_group_label>Teicoplanin antimicrobial-lock</arm_group_label>
    <other_name>teicoplanin: targocid 200 mg vial.</other_name>
    <other_name>sodium heparin 1%, 5000 IU/5ml.</other_name>
    <other_name>sodium chloride 0,9% 10 ml vial.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linezolid antimicrobial-lock solution</intervention_name>
    <description>Randomization of 5 patients into linezolid antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.</description>
    <arm_group_label>Linezolid antimicrobial-lock</arm_group_label>
    <other_name>linezolid: zyloxid 2 mg/ml, 300 ml vial.</other_name>
    <other_name>sodium heparin 1%, 5000 IU/5ml.</other_name>
    <other_name>sodium chloride 0,9% 10 ml vial.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daptomycin antimicrobial-lock solution</intervention_name>
    <description>Randomization of 5 patients into daptomycin antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.</description>
    <arm_group_label>Daptomycin antimicrobial-lock</arm_group_label>
    <other_name>daptomycin: cubicin 350 mg vial.</other_name>
    <other_name>sodium heparin 1%, 5000 IU/5ml.</other_name>
    <other_name>lactated ringer´s solution 500 ml viaflo.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tigecycline antimicrobial-lock solution</intervention_name>
    <description>Randomization of 5 patients into tigecycline antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.</description>
    <arm_group_label>Tigecycline antimicrobial-lock</arm_group_label>
    <other_name>tigecycline: tygacil 50 mg vial.</other_name>
    <other_name>sodium chloride 0,9% 10 ml vial.</other_name>
    <other_name>sodium heparin 1%, 5000 IU/5ml.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Intravenous access port recently inserted (≤ 3 days of insertion).

          -  Intravenous access port inserted more than 3 days before informed consent form signing
             patient. In this case, a blood sample from the catheter will be drawn for blood
             culture before administration of the antibiotic lock solution.

          -  Informed Consent Form Signed.

        Exclusion Criteria:

          -  Patients with confirmed or suspected local or systemic infection related to the
             catheter.

          -  Reported allergy or intolerance to the antibiotic employed for study lock solutions.

          -  Patients receiving oral, intravenous or intramuscular antibiotic treatment at the
             moment of inclusion in the clinical trial.

          -  Patients receiving oral, intravenous or subcutaneous anticoagulant treatment, in a
             higher dose than the one used for venous thrombosis prophylaxis at the moment of
             inclusion in the clinical trial.

          -  Patients younger than 18 years old.

          -  Pregnant women or women in nursing period.

          -  Personal incapacity to subscribe the informed consent to participate in the clinical
             trial.

        Patient Replacement Criteria:

        All patients and/or their legal representatives will be inform that they can leave the
        clinical trial in whenever they wish to do it, without prejudice to their medical
        attention.

        Also, according to the criteria of the principal investigator, a patient could be separated
        from the clinical trial. The reasons to separate a patient from the study and replace
        him/her are:

          -  Severe adverse reaction that could threat the life of the patient.

          -  Resolution of the patient or from his/her legal representative to abandon the study.

          -  No attend to the extraction visit date.

          -  Development of clinical inconveniences that may indicate to abandon the study in
             behalf of the patient.

          -  While antibiotic lock solution is within the port, manipulation or use of the port for
             administration of any kind of medication or fluid.

          -  Impossibility to extract 4 ml of the antibiotic lock solution from the port.

          -  Impossibility to extract 5 ml of peripheral blood sample at the moment of extraction
             of the antibiotic lock solution.

          -  Use of any of the prohibited medications during the antibiotic lock solution is inside
             the port.

          -  Intentionally wish of the patient in abandoning the study before or after antibiotic
             lock solution has been administered, or while the antibiotic lock solution is inside
             the port.

        All patients who abandon the study or would be separated from the study for the exposed
        reasons, will be replaced for new candidates who fulfil the inclusion criteria and have
        signed the informed consent form.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JOSE L DEL POZO, MD. Ph. D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinica Universidad de Navarra</affiliation>
  </overall_official>
  <overall_official>
    <last_name>CESAR E BUSTOS, MD.</last_name>
    <role>Study Chair</role>
    <affiliation>Clinica Universidad de Navarra</affiliation>
  </overall_official>
  <overall_official>
    <last_name>AITZIBER AGUINAGA, Pharm. D.</last_name>
    <role>Study Chair</role>
    <affiliation>Clinica Universidad de Navarra</affiliation>
  </overall_official>
  <overall_official>
    <last_name>JOSE R YUSTE, MD. Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Clinica Universidad de Navarra</affiliation>
  </overall_official>
  <overall_official>
    <last_name>JOSE R AZANZA, MD. Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Clinica Universidad de Navarra</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <results_reference>
    <citation>Del Pozo JL, Rodil R, Aguinaga A, Yuste JR, Bustos C, Montero A, Espinosa G, García-Fernández N. Daptomycin lock therapy for grampositive long-term catheter-related bloodstream infections. Int J Clin Pract. 2012 Mar;66(3):305-8. doi: 10.1111/j.1742-1241.2011.02830.x.</citation>
    <PMID>22340450</PMID>
  </results_reference>
  <results_reference>
    <citation>Del Pozo JL, García Cenoz M, Hernáez S, Martínez A, Serrera A, Aguinaga A, Alonso M, Leiva J. Effectiveness of teicoplanin versus vancomycin lock therapy in the treatment of port-related coagulase-negative staphylococci bacteraemia: a prospective case-series analysis. Int J Antimicrob Agents. 2009 Nov;34(5):482-5. doi: 10.1016/j.ijantimicag.2009.06.020. Epub 2009 Aug 26.</citation>
    <PMID>19713086</PMID>
  </results_reference>
  <results_reference>
    <citation>del Pozo JL. Role of antibiotic lock therapy for the treatment of catheter-related bloodstream infections. Int J Artif Organs. 2009 Sep;32(9):678-88. Review.</citation>
    <PMID>19882553</PMID>
  </results_reference>
  <results_reference>
    <citation>Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O'Grady NP, Raad II, Rijnders BJ, Sherertz RJ, Warren DK. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2009 Jul 1;49(1):1-45. doi: 10.1086/599376. Erratum in: Clin Infect Dis. 2010 Apr 1;50(7):1079. Dosage error in article text. Clin Infect Dis. 2010 Feb 1;50(3):457.</citation>
    <PMID>19489710</PMID>
  </results_reference>
  <results_reference>
    <citation>del Pozo JL, Patel R. The challenge of treating biofilm-associated bacterial infections. Clin Pharmacol Ther. 2007 Aug;82(2):204-9. Epub 2007 May 30. Review.</citation>
    <PMID>17538551</PMID>
  </results_reference>
  <results_reference>
    <citation>Sherertz RJ, Boger MS, Collins CA, Mason L, Raad II. Comparative in vitro efficacies of various catheter lock solutions. Antimicrob Agents Chemother. 2006 May;50(5):1865-8.</citation>
    <PMID>16641463</PMID>
  </results_reference>
  <results_reference>
    <citation>Fennell JP, O'Donohoe M, Cormican M, Lynch M. Linezolid lock prophylaxis of central venous catheter infection. J Med Microbiol. 2008 Apr;57(Pt 4):534-5. doi: 10.1099/jmm.0.47665-0.</citation>
    <PMID>18349379</PMID>
  </results_reference>
  <results_reference>
    <citation>LaPlante KL, Mermel LA. In vitro activity of daptomycin and vancomycin lock solutions on staphylococcal biofilms in a central venous catheter model. Nephrol Dial Transplant. 2007 Aug;22(8):2239-46. Epub 2007 Apr 1.</citation>
    <PMID>17403700</PMID>
  </results_reference>
  <results_reference>
    <citation>Del Pozo JL, Alonso M, Serrera A, Hernaez S, Aguinaga A, Leiva J. Effectiveness of the antibiotic lock therapy for the treatment of port-related enterococci, Gram-negative, or Gram-positive bacilli bloodstream infections. Diagn Microbiol Infect Dis. 2009 Feb;63(2):208-12. doi: 10.1016/j.diagmicrobio.2008.10.004. Epub 2008 Nov 21.</citation>
    <PMID>19026506</PMID>
  </results_reference>
  <results_reference>
    <citation>Raad I, Hanna H, Jiang Y, Dvorak T, Reitzel R, Chaiban G, Sherertz R, Hachem R. Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob Agents Chemother. 2007 May;51(5):1656-60. Epub 2007 Mar 12.</citation>
    <PMID>17353249</PMID>
  </results_reference>
  <results_reference>
    <citation>Robinson JL, Tawfik G, Saxinger L, Stang L, Etches W, Lee B. Stability of heparin and physical compatibility of heparin/antibiotic solutions in concentrations appropriate for antibiotic lock therapy. J Antimicrob Chemother. 2005 Nov;56(5):951-3. Epub 2005 Sep 9.</citation>
    <PMID>16155063</PMID>
  </results_reference>
  <results_reference>
    <citation>Labthavikul P, Petersen PJ, Bradford PA. In vitro activity of tigecycline against Staphylococcus epidermidis growing in an adherent-cell biofilm model. Antimicrob Agents Chemother. 2003 Dec;47(12):3967-9.</citation>
    <PMID>14638511</PMID>
  </results_reference>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2012</study_first_submitted>
  <study_first_submitted_qc>May 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2012</study_first_posted>
  <last_update_submitted>February 18, 2015</last_update_submitted>
  <last_update_submitted_qc>February 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Clinica Universidad de Navarra, Universidad de Navarra</investigator_affiliation>
    <investigator_full_name>José Luis del Pozo</investigator_full_name>
    <investigator_title>Medical Doctor, Ph. D.</investigator_title>
  </responsible_party>
  <keyword>Antibiotic-lock technique.</keyword>
  <keyword>In vivo antimicrobial concentration.</keyword>
  <keyword>Antimicrobial bioactivity.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacteremia</mesh_term>
    <mesh_term>Catheter-Related Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Linezolid</mesh_term>
    <mesh_term>Daptomycin</mesh_term>
    <mesh_term>Tigecycline</mesh_term>
    <mesh_term>Minocycline</mesh_term>
    <mesh_term>Teicoplanin</mesh_term>
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Anti-Infective Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

